In this retrospective study we therefore hypothesized that the basal values and changes in metabolic assessment before and during therapy with everolimus could reflect the inhibition of mTOR in the cancer cell and could serve as predictors of clinical efficacy of treatment with everolimus in mRCC. The gene discussed is MTOR; the disease is cancer.